PL2578212T3 - Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych - Google Patents

Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych

Info

Publication number
PL2578212T3
PL2578212T3 PL10852058T PL10852058T PL2578212T3 PL 2578212 T3 PL2578212 T3 PL 2578212T3 PL 10852058 T PL10852058 T PL 10852058T PL 10852058 T PL10852058 T PL 10852058T PL 2578212 T3 PL2578212 T3 PL 2578212T3
Authority
PL
Poland
Prior art keywords
neurogenerative
erk1
illnesses
enzyme
treatment
Prior art date
Application number
PL10852058T
Other languages
English (en)
Inventor
Medrano Pilar Navarro
Puigjane Elisabet Gregori
Del Olmo Marisol Montolio
Redondo Ana Jiménez
López Jordi Mestres
Original Assignee
Farmalider Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider Sa filed Critical Farmalider Sa
Publication of PL2578212T3 publication Critical patent/PL2578212T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10852058T 2010-05-24 2010-05-24 Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych PL2578212T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/ES2010/000228 WO2011147999A1 (es) 2010-05-24 2010-05-24 Compuesto inhibidor de la activación de la enzima erk1/2 para su uso en el tratamiento de enfermedades neurodegenerativas
EP10852058.6A EP2578212B1 (en) 2010-05-24 2010-05-24 Compound inhibiting activation of the enzyme erk1/2 for use in the treatment of neurogenerative illnesses

Publications (1)

Publication Number Publication Date
PL2578212T3 true PL2578212T3 (pl) 2017-01-31

Family

ID=45003358

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10852058T PL2578212T3 (pl) 2010-05-24 2010-05-24 Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych

Country Status (4)

Country Link
US (1) US9000047B2 (pl)
EP (1) EP2578212B1 (pl)
PL (1) PL2578212T3 (pl)
WO (1) WO2011147999A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX378579B (es) 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
TW202144000A (zh) * 2020-03-24 2021-12-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療帕金森氏症的方法和藥物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061774A (en) 1974-03-02 1977-12-06 Lilly Industries, Limited Halogenated amino methyl adamantane derivatives
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
GB9901691D0 (en) 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
US20050113458A1 (en) 2003-10-22 2005-05-26 Forest Laboratories, Inc. Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
US8044100B2 (en) 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
EP1746092A1 (en) 2005-07-22 2007-01-24 Exonhit Therapeutics SA Compounds and methods for treatment of amyloid-B-peptide related disorders
US20100298278A1 (en) 2005-08-11 2010-11-25 Christian Eickmeier Inhibitors of beta-secretase for the treatment of alzheimer's disease
JP2009504612A (ja) 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
JP2009504614A (ja) 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
CA2618474A1 (en) 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
ES2341517B1 (es) * 2008-03-28 2011-01-25 Farmalider, S.A Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas.

Also Published As

Publication number Publication date
EP2578212B1 (en) 2016-07-06
EP2578212A4 (en) 2013-11-06
EP2578212A1 (en) 2013-04-10
US20130065966A1 (en) 2013-03-14
US9000047B2 (en) 2015-04-07
WO2011147999A1 (es) 2011-12-01

Similar Documents

Publication Publication Date Title
HRP20181185T1 (hr) Inhibitori ibat za liječenje bolesti jetre
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
PL2646425T3 (pl) Kwasy indanyloksydihydrobenzofuranylooctowe użyteczne do leczenia zespołu metabolicznego
PT3042910T (pt) 2'-espiro-nucleósidos para utilização na terapia da hepatite c
AP2013006984A0 (en) BicycloÄ3.2.1Üoctyl amide derivatives and uses of same
PL2391650T3 (pl) Sposoby leczenia dny
ZA201104146B (en) Dispersions comprising inhibitors of the hydroxyphenylpyruvate-dioxygenase
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
ZA201205432B (en) Compositions and methods for the diagnosis and treatment of tumor
IL223865A0 (en) Calcium salts of dihydrooroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof
PL2521703T3 (pl) Związki fosforanowe i ich zastosowanie jako nawozu
EP2538791A4 (en) Growth Factor Compositions From Thrombocytes And Methods Of Treating Tendinopathia
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
PL2578212T3 (pl) Związek hamujący aktywację enzymu Erk 1/2 do zastosowania w leczeniu chorób neurodegeneracyjnych
LT2460509T (lt) Kompozicija, skirta karpų gydymui
GB201016486D0 (en) Compounds for the use in treatment of plants
EP2544534A4 (en) COMPOSITIONS, METHODS AND DEVICES USED IN THE TREATMENT OF DYSMENORRHEA
PL2229943T3 (pl) Związek do zastosowania w leczeniu neuropatii obwodowych
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
ZA201107562B (en) Compound for the treatment of tuberculosis
AP2675A (en) The distrubution of eletricity
HK1163531A (en) Compound for the treatment of tuberculosis
GB0703491D0 (en) The treatment of hyperhidrosis
GB0703492D0 (en) The treatment of hyperhidrosis
GB0809319D0 (en) The treatment of puritus